Colorectal cancer is the third leading cause of cancer mortality in the U.S. The American Cancer Society estimates that this year alone, there will be 106,180 new cases of colon cancer diagnosed.
Two promising new studies have found that certain cannabinoids— including CBD, CBDV, CBG, CBGV, and CBL— can eliminate the growth of harmful colorectal cancer cells in humans. These studies offer a guiding light to those researching cannabinoids for cancer treatment, although they are limited in their scope.
THC was not able to be included in the research group in either study due to regulations that don’t allow certain scientists to study it. The “psychoactive” cannabinoid was left out of the picture. But the studies do indicate that entourage effect with other cannabinoids like CBD, CBG, and CBL working in concert help to propel the “anti-proliferative” effect. One of the studies even points to the entourage effect with cannabinoids and mushroom extracts working together to reduce the cancer cells.
Cannabotech’s Integrative-Colon Study Eliminates 90% of Cancer Cells in Model
A new product coming to market in the U.S., U.K. and Israel in the fall of 2022 has been found to eliminate over 90% of colon cancer cells in a cell model. The product, called Cannabotech Integrative-Colon, used a combination of medicinal, non-psychoactive mushrooms and various cannabinoids to target colorectal cancer cells.
Cannabotech did not use psilocybin, the most common psychoactive mushroom, for this study. Nor did they study THC, only the other non-psychoactive cannabinoids. Today, there are over 100 known cannabinoids. I spoke with the study’s lead researchers, Professor Tami Peretz, a senior oncologist at Hadassah Ein Kerem Hospital, and Dr. Isaac Angel, a pharmacologist specializing in drug development, who explained more of their findings.
